1. Home
  2. BNGO vs LEXX Comparison

BNGO vs LEXX Comparison

Compare BNGO & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bionano Genomics Inc.

BNGO

Bionano Genomics Inc.

HOLD

Current Price

$1.10

Market Cap

11.6M

Sector

Industrials

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$0.75

Market Cap

16.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNGO
LEXX
Founded
2003
2004
Country
United States
Canada
Employees
N/A
7
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.6M
16.2M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
BNGO
LEXX
Price
$1.10
$0.75
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$6.33
$1.50
AVG Volume (30 Days)
93.3K
132.5K
Earning Date
03-30-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$12,000,735.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$24.27
$601.47
P/E Ratio
N/A
N/A
Revenue Growth
26.26
N/A
52 Week Low
$1.06
$0.46
52 Week High
$5.50
$1.90

Technical Indicators

Market Signals
Indicator
BNGO
LEXX
Relative Strength Index (RSI) 38.05 52.27
Support Level $1.07 $0.58
Resistance Level $1.18 $0.87
Average True Range (ATR) 0.04 0.09
MACD 0.01 0.00
Stochastic Oscillator 29.21 44.30

Price Performance

Historical Comparison
BNGO
LEXX

About BNGO Bionano Genomics Inc.

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: